Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP4536)
Name
Calcipotriol
Synonyms
Calcipotriol; calcipotriene; Dovonex; Daivonex; Psorcutan; Sorilux; 112965-21-6; Calcitrene; MC 903; MC-903; Calcipotriol hydrate; UNII-143NQ3779B; CHEBI:50749; Dovonex (TN); 143NQ3779B; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; 112828-00-9; NCGC00167465-01; Calciptriol; DSSTox_CID_26648; DSSTox_RID_81793; DSSTox_GSID_46648; Divonex; (22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrovitamin D3 / (22E)-(24S)-1alpha,24-dihydroxy-26,27-cyclo-22,23-didehydrocholecalciferol / Calcipotriol; (5Z,7E,22E)-(1S,3R,24S)-26,27-cyclo-9,10-seco-5,7,10(19),22-cholestatetraene-1,3,24-triol; SMR000466353; CAS-112965-21-6; Calcipotriene [USAN]; SR-01000762910; CCRIS 7700; MFCD10567086; (5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol; PRI 2201; Calcipotriol (JAN); Calcipotriol [INN]; Calcipotriene (USP); BMS-181161; PubChem18810; PubChem19334; Epitope ID:114242; SCHEMBL2853; MLS000759467; MLS001424130; GTPL2778; CHEMBL1200666; DTXSID0046648; AMY2864; 1s19; HMS2051N11; HMS2089J08; HMS3269P03; HMS3413D04; HMS3677D04; HMS3713K08; MC903; EX-A4430; PRI-2201; ZINC3921872; Tox21_112469; BDBM50369964; LMST03020106; s3739; AKOS015855239; Tox21_112469_1; CCG-100949; CS-0387; DB02300; NC00199; STF-115469; NCGC00167465-02; AS-56390; CPD000466353; HY-10001; O763; D01125; U-0267; W-5148; 24207-EP2275420A1; 24207-EP2295055A2; 24207-EP2295416A2; 24207-EP2298748A2; 24207-EP2298764A1; 24207-EP2298765A1; 24207-EP2305640A2; 24207-EP2305642A2; 24207-EP2308861A1; 24207-EP2311453A1; 24207-EP2314590A1; AB00698343-05; 828C009; Q155683; SR-01000762910-3; SR-01000762910-4; (1?,3?,5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1,3,24-triol; (1S,3R,5Z,7E,14beta,17alpha,22E,24S)-26,27-cyclo-9,10-secocholesta-5,7,10,22-tetraene-1,3,24-triol; (5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol hydrate; (5Z,7E,24S)-26,27-Cyclo-9,10-secocholesta-5,7,10(19),22-tetraene-1alpha,3beta,24-triol; 9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1alpha,3beta,5Z,7E,22E,24S)-
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Plaque psoriasis [ICD-11: EA90] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C27H40O3
PubChem CID
5288783
Canonical SMILES
CC(C=CC(C1CC1)O)C2CCC3C2(CCCC3=CC=C4CC(CC(C4=C)O)O)C
InChI
1S/C27H40O3/c1-17(6-13-25(29)20-8-9-20)23-11-12-24-19(5-4-14-27(23,24)3)7-10-21-15-22(28)16-26(30)18(21)2/h6-7,10,13,17,20,22-26,28-30H,2,4-5,8-9,11-12,14-16H2,1,3H3/b13-6+,19-7+,21-10-/t17-,22-,23-,24+,25-,26+,27-/m1/s1
InChIKey
LWQQLNNNIPYSNX-UROSTWAQSA-N
CAS Number
CAS 112965-21-6
ChEBI ID
CHEBI:50749
TTD Drug ID
D01QUS
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Betamethasone dipropionate      Psoriasis     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)
The fixed combination treatment improves quality of life to a significantly greater extent than calcipotriol, with the once daily regimen most appreciated by patients, in both active disease and recurrency.
Target and Pathway
Target(s) Vitamin D3 receptor (VDR)  Molecule Info  [3]
KEGG Pathway Endocrine and other factor-regulated calcium reabsorption Click to Show/Hide
2 Mineral absorption
3 Tuberculosis
NetPath Pathway IL4 Signaling Pathway Click to Show/Hide
Panther Pathway Vitamin D metabolism and pathway Click to Show/Hide
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling Click to Show/Hide
2 Direct p53 effectors
3 RXR and RAR heterodimerization with other nuclear receptor
4 Retinoic acid receptors-mediated signaling
5 Validated transcriptional targets of deltaNp63 isoforms
6 Validated transcriptional targets of TAp63 isoforms
Reactome Nuclear Receptor transcription pathway Click to Show/Hide
WikiPathways Ovarian Infertility Genes Click to Show/Hide
2 Nuclear Receptors in Lipid Metabolism and Toxicity
3 Nuclear Receptors Meta-Pathway
4 Vitamin D Receptor Pathway
5 Drug Induction of Bile Acid Pathway
6 Nuclear Receptors
7 Vitamin D Metabolism
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2778).
Reference 2 Consensus on the use of the fixed combination calcipotriol/betamethasone dipropionate in the treatment of plaque psoriasis. G Ital Dermatol Venereol. 2012 Dec;147(6):609-24.
Reference 3 Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr Drug Targets. 2008 Apr;9(4):345-59.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China